Maa: Yhdysvallat
Kieli: englanti
Lähde: NLM (National Library of Medicine)
CHOLINE C-11 (UNII: M4AS4XGD4Q) (CHOLINE C-11 - UNII:M4AS4XGD4Q)
UCSF Radiopharmaceutical Facility
CHOLINE C-11
CHOLINE C-11 33.1 mCi in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Choline C 11 Injection is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. In clinical studies, images were produced with PET/CT coregistration. Limitation of U se: 11 C-choline PET imaging is not a replacement for histologic verification of recurrent prostate cancer. None. Pregnancy Category C. There are no adequate and well controlled studies with Choline C 11 Injection in pregnant women and the fetal radiation dose from a 11 C-choline PET imaging study is unknown. It is not known whether Choline C 11 Injection can cause fetal harm when administered to a pregnant w
Choline C 11 Injection is packaged in a multiple-dose glass vial containing between 148 MBq to 1,225 MBq (4 mCi to 33.1 mCi) per milliliter of 11 C-choline at EOS calibration time in aqueous 0.9% sodium chloride solution. Store Choline C 11 Injection at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F) (see USP Controlled Room Temperature). Use the solution within 120 minutes of EOS calibration.
Abbreviated New Drug Application
CHOLINE C 11- CHOLINE C-11 INJECTION UCSF RADIOPHARMACEUTICAL FACILITY ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE CHOLINE C 11 INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CHOLINE C 11 INJECTION. CHOLINEC 11 INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 2012 INDICATIONS AND USAGE Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging. In these patients, C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. In clinical studies, images were produced with PET/CT coregistration. Limitation of Use: C-choline PET imaging is not a replacement for histologic verification of recurrent prostate cancer (1). DOSAGE AND ADMINISTRATION Aseptically withdraw Choline C 11 Injection from its container and administer 370 – 740 MBq (10 – 20 mCi) as a bolus intravenous injection. The radioactivity dose (370 – 740 MBq, 10 – 20 mCi) is chosen based on patient body dimensions and the characteristics of the image acquisition system (2.1). Initiate imaging immediately after administration of Choline C 11 Injection and acquire static emission images 0 – 15 minutes from the time of injection (2.5). The effective radiation absorbed dose from 740 MBq (20 mCi) dose of Choline C 11 Injection is approximately 3.22 mSv (0.32 rem) in an adult (2.4). Image interpretation: Refer to full prescribing information (2.5). DOSAGE FORMS AND STRENGTHS Choline C 11 Injection contains 148 – 1,225 MBq (4 – 33.1 mCi) per milliliter of C-choline at end of synthesis calibration time in aqueous 0.9% sodium chloride solution (3). CONTRAINDICATIONS None (4). Lue koko asiakirja